Abstract:Pancreatic cancer (PC) carries a poor prognosis among all malignancies and poses great challenges to clinical drug accessibility due to the severely fibrotic and hypoxic tumor microenvironment (TME). Therein, cancer-associated fibroblasts (CAFs), which are extremely abundant in PC, play a key role in forming the complex PC microenvironment. Therefore, a highly efficient TME reprogramming therapeutic paradigm that can specifically inhibit CAF function is urgently needed. Herein, we successfully developed a novel CAF-tailored nanosystem (Dex-GP-DOCA, DPD) loaded with a potent anti-fibrosis flavonoid compound (Quercetin, QUE), which possesses biological responsiveness to fibroblast activation protein alpha (FAP-α), prolonged TME remodeling and enhancement of clinical chemotherapeutics. Specifically, DPD/QUE allowed for extracellular matrix (ECM) reduction, vessel normalization, hypoxia-induced drug resistance reversal, and blockade of Wnt16 paracrine in CAFs. More importantly, this chemotherapy conducive microenvironment persisted for at least 8 days following treatment with DPD/QUE. It should also be noted that the effective and prolonged microenvironment modulation induced by DPD/QUE significantly improved the chemotherapy sensitivity of Abraxane and gemcitabine, the first-line chemotherapeutic drugs for PC, with inhibition rates increasing from 37.5% and 40.0% to 87.5% and 85.2%, respectively. Overall, our CAFs-targeted nanosystem showed promising prospects for remodeling the TME and facilitating chemotherapy for refractory pancreatic cancer.

Progress and reflection on the therapeutic strategy of targeting the pancreatic cancer microenvironment

Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective

Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.

New Potential Therapeutic Strategy of Pancreatic Cancer via Targeting the Tumor Microenvironment

Immunotherapy in Pancreatic Cancer: New Hope or Mission Impossible?

Chemotherapy and tumor microenvironment of pancreatic cancer

Regulation of tumor microenvironment for pancreatic cancer therapy

Research Progress in Tumor Microenvironment of Pancreatic Cancer

Advances in microenvironment and metastasis of pancreatic cancer

Fundamental insights and molecular interactions in pancreatic cancer: Pathways to therapeutic approaches

Immunosuppression, Immune Escape, and Immunotherapy in Pancreatic Cancer: Focused on the Tumor Microenvironment

Different therapies in pancreatic cancer treatment

Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment

MicroRNAs: emerging biomarkers and therapeutic targets in pancreatic cancer

Focus on Pancreatic Cancer Microenvironment

Selection and therapeutic effect evaluation of chemotherapy regimens for pancreatic cancer

Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer

Progress on the Role of Reactive Oxygen Species-Mediated Tumor Microenvironment in Pancreatic Cancer

Immune status of pancreatic cancer patient and progress in immunotherapy

Enhancing Chemotherapy for Pancreatic Cancer Through Efficient and Sustained Tumor Microenvironment Remodeling with a Fibroblast-Targeted Nanosystem.

Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches